Replies to post #143298 on Biotech Values

[whocares]

Geez, I totally forgot about EXAS(molecular diagnostics company). I will keep an eye on any developments. Thanks

[DewDiligence]

ABT declares 354th consecutive quarterly dividend:

http://finance.yahoo.com/news/abbott-declares-354th-consecutive-quarterly-140900606.html

For those who don’t have a calculator handy, that’s 88.5 years! Moreover, the dividend has been increased at least once per year for the past 40 years.

[DewDiligence]

PropThink (a firm I’d never heard of) is pumping EXAS by issuing a PR linking to a month-old interview with the CEO:

http://finance.yahoo.com/news/exact-sciences-ceo-3-billion-113401252.html

I like EXAS, so I’m somewhat dismayed by its connection to an outfit like PropThink.

[DewDiligence]

AGN Shares Climb on Strong Botox Growth

[AGN was +4.3% today, which is a very big move for such a stable stock. Botox sales (for cosmetic and medical uses) grew 14% YoY in local currencies. In the US market, Botox for medical (non-cosmetic) indications had a whopping 93% market share, despite the presence of three other neurotoxins on the market (Dysport, Xeomin, and Myobloc). Botox is closing in on a $2B annualized run rate, which is not bad for a drug that a regular poster on this board called "ridiculous."]

http://www.bloomberg.com/news/2012-08-01/allergan-rises-the-most-in-3-years-as-botox-sales-lift-profit.html

›By Jeanna Smialek - Aug 1, 2012 3:48 PM ET

Allergan Inc. climbed the most in three years after second-quarter earnings beat analyst estimates and the company raised the lower end of its full-year forecast.

Allergan gained 4.7 percent to $85.95 at 3:45 p.m. New York time. The shares of the Irvine, California-based company rose to as high as $91.94, their biggest intraday increase since March 2009. Earnings excluding some items of $1.07 a share beat by 1 cent the average of 22 analyst estimates compiled by Bloomberg.

[Non-GAAP] earnings for 2012 will be $4.15 to $4.19 a share, the company said, increasing the lower end of the outlook by 2 cents. Botox sales increased 10 percent to $461.2 million in the second quarter, while revenue from southern Europe wasn’t hurt by the debt crisis, the company said. [On a constant-currency basis, Botox sales grew 14% YoY.]

“We have just some fabulous growth rates, even in the so- called old Europe,” David Pyott, Allergan CEO, said on a conference call with analysts.

Allergan has more than half the European breast implant market share, which is split between 11 companies, Pyott said in a later telephone interview. Worldwide sales growth for the Allergan’s implants has been 14 percent this year, he said.

“The market doesn’t seem to have taken a hit,” Pyott said.‹

[DewDiligence]

PKI posts solid quarter on growth in emerging markets:

http://www.reuters.com/article/2012/08/02/perkinelmer-results-idUSL2E8J2EYS20120802

PerkinElmer Inc reported higher-than-expected second quarter profit on Thursday as solid demand for its scientific and environmental products in the United States and emerging markets offset declines in Europe.

Bucking a trend seen with some of its peers that had to pull back on full-year forecasts, PerkinElmer maintained its 2012 outlook for [non-GAAP] earnings of $2.00 to $2.05 per share…and for organic revenue growth [i.e. excluding acquisitions and currency effects] in mid-single digit range.

…[Non-GAAP], the company earned 53 cents per share, topping analysts' average expectations by 4 cents, according to Thomson Reuters I/B/E/S.

…sales in the Americas grew by mid-single digits and…revenue from China was up by more than 20 percent.

"I think we will continue to see decent growth in the Americas, and of course in the emerging markets, which represented about 28% of revenue and contributed about half of organic growth," [CEO Rovert Friel] said, adding that South America, particularly Brazil, continued to be quite strong.

"Those countries are really focused on environmental concerns and improving healthcare, and we can help them there."